Cell Therapeutics said yesterday it has agreed to sell Trisenox, a drug for a rare form of leukemia, to Cephalon for $70 million in cash...
Cell Therapeutics said yesterday it has agreed to sell Trisenox, a drug for a rare form of leukemia, to Cephalon for $70 million in cash.
The Seattle biotech company said it will receive about $30 million from the transaction; it is required to pay the rest to PharmaBio Development, which had secured some future rights to the drug in December. Trisenox is the company’s only marketed drug.
Cephalon will take over sales, marketing and development of the drug, and will offer jobs to between 20 and 40 employees of Cell Therapeutics who work on Trisenox, said Susan Callahan, a spokeswoman for Cell Therapeutics. Cephalon, based in Frazer, Pa., also will pay royalties on future worldwide sales of Trisenox.
Cell Therapeutics disclosed last week that it is cutting 75 jobs in Seattle to conserve cash, after its leading drug candidate, Xyotax, failed in a pivotal trial this spring. Through last week’s layoffs, yesterday’s sale of Trisenox, and attrition, the company has shed 130 jobs, Callahan said. That leaves it with about 270 employees in the U.S. and Europe.
Most Read Stories
- Man shot at UW no racist, friends insist, despite shooter’s claim
- We need real solutions to vehicle campers | Editorial
- Crowd comparison: Inauguration Friday and women's march Saturday
- Man struck, killed by Link light-rail train in Rainier Valley
- Will Seahawks keep Luke Willson? That's among questions facing tight end position in offseason
The company’s strategy is to file for FDA approval of Xyotax for lung cancer.
Trisenox, first approved by the FDA in 2000, had sales of $26.6 million in 2004. In the past, the company has said it expected the drug to reach $100 million a year in sales.
Its first-quarter sales were $6 million, up 54 percent from the same period in 2004.
Luke Timmerman: 206-515-5644 or firstname.lastname@example.org